Development of high affinity broadly reactive aptamers for spike protein of multiple SARS-CoV-2 variants.

We have developed broadly reactive aptamers against multiple variants by alternating the target between spike proteins from different SARS-CoV-2 variants during the selection process. In this process we have developed aptamers which can recognise all variants, from the original wild-type 'Wuhan' strain to Omicron, with high affinity ( K d values in the pM range).